

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

TNF-? Antibody, anti-human, PE-Vio® 770

RRID:AB_2784483

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-120-492, RRID:AB_2784483

Antibody Information

URL: http://antibodyregistry.org/AB_2784483

Proper Citation: Miltenyi Biotec Cat# 130-120-492, RRID:AB_2784483

Target Antigen: TNF-?

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-096-755. (RRID:AB_2661081).

Antibody Name: TNF-? Antibody, anti-human, PE-Vio® 770

Description: This monoclonal targets TNF-?

Target Organism: human

Clone ID: clone cA2

Antibody ID: AB_2784483

Vendor: Miltenyi Biotec

Catalog Number: 130-120-492

Record Creation Time: 20250820T000912+0000

Record Last Update: 20250820T073037+0000

Ratings and Alerts

No rating or validation information has been found for TNF- α Antibody, anti-human, PE-Vio® 770.

No alerts have been found for TNF- α Antibody, anti-human, PE-Vio® 770.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Schmidlin T, et al. (2025) MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens. *Cell reports methods*, 5(8), 101120.

Augello M, et al. (2024) Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV. *iScience*, 27(1), 108673.

Saggau C, et al. (2024) Autoantigen-specific CD4⁺ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. *Immunity*, 57(10), 2416.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. *Cell*, 186(16), 3333.

Dolton G, et al. (2022) Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. *Cell*, 185(16), 2936.

Saggau C, et al. (2022) The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. *Immunity*, 55(10), 1924.

Bacher P, et al. (2020) Low-Avidity CD4⁺ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity*, 53(6), 1258.